Second-quarter fiscal 2009 results announced by Rosetta Genomics

Editorial Checklist Reviewed
Sep 9 2009NewsGuard 100/100 Score

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and six months ended June 30, 2009. Highlights of the second quarter of 2009 and subsequent weeks include:

  • Entering into exclusive distribution agreements with Warnex Laboratories, Super Religare Laboratories and AXA Diagnostics for our first three cancer diagnostic tests, miRview™ mets, miRview™ squamous and miRview™ meso
  • Receiving clearance from the states of California, Maryland and Rhode Island for our CLIA-certified laboratory, bringing the total to 48 U.S. states
  • Continuing development of our colon cancer screening test

  • Selling Parkway Clinical Laboratories for up to $2.5 million

  • Announcing plans for Amir Avniel to step down as chief executive officer of Rosetta Genomics once a successor is in place in order to lead Rosetta Green, the company’s early stage, cleantech division

Source:

http://www.rosettagenomics.com 

Posted in:

Tags: , , , , , , , , , , ,

Comments (0)

Suggested Reading

MIT team creates efficient technique for identifying causal gene relationships
Stilla Technologies with Source BioScience brings advanced genomics solutions to the UK market
Mapping human biology: Human Cell Atlas leads a new era in precision medicine
New atlas maps 1.6 million human gut cells in unprecedented detail
Breakthrough research reveals how to target malignant DNA in aggressive cancers
Barcelona launches world’s first joint program on evolutionary medical genomics
New antibiotic-resistant bacteria strain may be spreading across Asia
First 'blueprint' of human skeletal development offers new insights into bone formation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Early genomic profiling improves cancer treatment outcomes